Sign in

    Nevin

    Director and Senior Equity Analyst at RBC Capital Markets

    Nevin Chittur is a Director and Senior Equity Analyst at RBC Capital Markets, specializing in coverage of the U.S. homebuilding and building products sector with a focus on companies such as Lennar, D.R. Horton, PulteGroup, and Masco. He is recognized for his in-depth fundamental research and market insights, maintaining a track record that includes a success rate exceeding 62% and an average annual return on recommendations of over 7%, as tracked by TipRanks. Nevin joined RBC Capital Markets in 2014 after previous equity research roles at UBS and Deutsche Bank, bringing over fifteen years of experience in analyzing housing-related equities. He holds FINRA Series 7, 63, and 86/87 certifications, affirming his regulatory credentials and commitment to professional standards.

    Nevin's questions to Xenon Pharmaceuticals (XENE) leadership

    Nevin's questions to Xenon Pharmaceuticals (XENE) leadership • Q4 2024

    Question

    Nevin from RBC Capital Markets, on for Brian Abrahams, asked about the market performance of competitor drug XCOPRI and how Azetukalner might fit into the treatment paradigm and compare in terms of sales potential.

    Answer

    CFO Sherry Aulin highlighted XCOPRI's strong sales as evidence of a significant commercial opportunity for novel agents. She positioned Azetukalner as potentially superior due to its lack of a lengthy titration, novel mechanism, and potential mood benefits. CMO Dr. Chris Kenney added that Azetukalner's seizure freedom data was achieved at a clinically relevant dose and without the severe allergic reactions associated with XCOPRI. CEO Ian Mortimer noted the overall strength of the epilepsy market supports a large opportunity.

    Ask Fintool Equity Research AI